newsfilter
← Latest News
PR Newswire·

Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

BIOA
  • Eisai reported preliminary global Leqembi sales of JPY 29.3 billion for Q2 2026.
  • BioArctic received a royalty of SEK 179 million, representing a 10% increase compared to Q2 2025.
  • Excluding a JPY 5.3 billion one-time stockpiling effect in China during Q2 2025, royalty revenues grew approximately 43% year-over-year.
  • BioArctic's full Q2 2026 report is scheduled for publication on August 26, 2026, at 08:00 CEST.
  • Leqembi is approved in 53 countries and currently under regulatory review in 6 countries.
  • Subcutaneous maintenance dosing every four weeks is approved in 8 countries, including the US, UK, China, and Japan.
  • The US subcutaneous formulation Leqembi Iqlik is approved for early Alzheimer's disease treatment.
  • Japan submitted a new drug application for the subcutaneous formulation in November 2025.
  • China included Leqembi in its Commercial Insurance Innovative Drug List in December 2025.
  • China accepted the Biologics License Application for the subcutaneous formulation in January 2026 and designated it for priority review in February 2026.
  • Eisai's Phase 3 AHEAD 3-45 study for preclinical Alzheimer's disease is ongoing since July 2020 after fully recruiting in October 2024.
  • The Tau NexGen study for Dominantly Inherited Alzheimer's disease is ongoing since January 2022 with lecanemab as the backbone therapy.
  • BioArctic maintains a long-term collaboration with Eisai for development, commercialization, and royalties on global sales.
  • BioArctic holds commercialization rights for Leqembi in the Nordic region.
  • BioArctic is a Swedish biopharma company listed on Nasdaq Stockholm with a focus on neurodegenerative disease treatments.